News Focus
News Focus
Replies to #68207 on Biotech Values
icon url

DewDiligence

11/05/08 2:44 PM

#68210 RE: iwfal #68207

ZGEN – I would expect the FDA’s guidance for phase-3 to consist of one RCT and one open-label safety study—similar to what the FDA is requiring for Telaprevir in the first-line setting.